Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the acute ocular pain market grown in recent years?

The market size for acute ocular pain has seen a robust expansion in the previous years. The market, which is predicted to increase from $0.40 billion in 2024 to $0.43 billion in 2025, will display a compound annual growth rate (CAGR) of 8.7%. Factors like an upsurge in eye injuries and ocular surgeries, heightened public cognizance about eye health, growing elderly population, quick urbanization, and increased spending on healthcare have all contributed significantly to the historical growth of this market.

How is the acute ocular pain market size expected to evolve during the forecast period?

The market for acute ocular pain is anticipated to experience robust growth in the forthcoming years. By 2029, it is projected to reach $0.60 billion, growing at a Compound Annual Growth Rate (CAGR) of 8.6%. This growth during the forecast period is credited to factors such as beneficial reimbursement plans, extended accessibility in emerging markets, elevated incidence of eye disorders, increased need for specialized and effective eye pain treatments, and growing emphasis on patient-focused care. Key tendencies highlighted for the forecast period comprise breakthroughs in diagnostic procedures, advancements in technology, inventive drug concoctions, unique delivery mechanisms, and the incorporation of artificial intelligence.

Get your acute ocular pain market report here!

https://www.thebusinessresearchcompany.com/report/acute-ocular-pain-global-market-report

Which key drivers are propelling the acute ocular pain market’s growth?

The surge in eye injury incidents is anticipated to drive the growth of the acute ocular pain market. Eye injuries encompass any harm or trauma inflicted on the eye or its adjacent structures, potentially from collisions, foreign materials, exposure to chemicals, or burns. Such incidents cause pain, can disrupt vision, and may bring about long-lasting damage. The increasing rate of eye injuries can be attributed to augmented workplace dangers, extended exposure to screens, environmental contaminants, injuries related to sports, and an absence of adequate eye protection. Acute ocular pain acts as a vital sign of underlying eye trauma, promoting prompt detection and treatment. However, delayed or insufficient pain management can magnify complications, leading to extended discomfort and possible vision loss. For example, as per the Welsh Government report in August 2024, there was a 5.8% increment in admissions to ophthalmology departments in Wales in the year 2023-24, totaling over 35,000 admissions compared to the preceding year. Thus, the escalating frequency of eye injuries is fueling the acute ocular pain market.

What are the market segments in the acute ocular pain industry?

The acute ocular pain market covered in this report is segmented –

1) By Drug: Topical Non-Steroidal Anti-Inflammatory Drugs, Topical Cycloplegic Agents, Oral Analgesics, Corticosteroids, Immunomodulators

2) By Medical Condition: Corneal Abrasion, Glaucoma, Conjunctivitis, Iritis, Other Medical Conditions

3) By Route Of Administration: Topical, Intraocular, Oral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Ophthalmic Clinics, Other End Users

Subsegments:

1) By Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ketorolac, Bromfenac, Nepafenac, Diclofenac

2) By Topical Cycloplegic Agents: Atropine, Cyclopentolate, Homatropine

3) By Oral Analgesics: Acetaminophen, Ibuprofen, Tramadol, Codeine

4) By Corticosteroids: Prednisolone, Dexamethasone, Fluorometholone, Loteprednol

5) By Immunomodulators: Cyclosporine, Tacrolimus, Lifitegrast

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21080&type=smp

Which leading companies are shaping the growth of the acute ocular pain market?

Major companies operating in the acute ocular pain market are AbbVie Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Alcon Vision LLC, Sun Pharmaceutical Industries Ltd., Bausch + Lomb Corporation, Santen Pharmaceutical, Dompé Farmaceutici S.p.A., Aldeyra Therapeutics Inc., Ocular Therapeutix, Nicox S.A., Omeros Corporation, Chromocell Therapeutics Corporation, XOMA Corporation, Vyluma, Sylentis, Surface Ophthalmics Inc., Pharmaleads, Kala Bio, IACTA Pharmaceuticals

What key trends are currently impacting the acute ocular pain market’s development?

Leading businesses in the acute ocular pain field are emphasizing the development of creative solutions including neuropathic corneal pain (NCP) therapy as a new treatment for intense eye pain. This NCP treatment is devised to manage and mitigate chronic, and frequently severe, corneal pain resulting from nerve injuries or malfunctions. For example, OKYO Pharma, a UK-based biopharmaceutical organization, began a Phase 2 clinical experiment with the first dose given to a patient with OK-101, a fresh neuropathic corneal pain (NCP) therapy, in October 2024. OK-101 is a non-opioid, anti-inflammatory treatment method aimed at addressing neuropathic corneal pain, a condition linked to corneal nerve damage and significant eye discomfort. They plan to recruit a total of 48 patients diagnosed with NCP, verified via confocal microscopy. This trial is overseen by Dr. Pedram Hamrah, a respected expert in the field of ocular pain management, and is taking place at Tufts Medical Center.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21080

Which geographic areas are influencing the growth of the acute ocular pain market?

Asia-Pacific was the largest region in the acute ocular pain market in 2024. North America expected to be the fastest-growing region in the forecast period. The regions covered in the acute ocular pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

PD 1 And PDL1 Inhibitors Immune Checkpoint Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Stem Cell Therapy Global Market Report 2025

https://thebusinessresearchcompany.com/report/stem-cells-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: